Do analysts rate OGI or CMED?

Organigram currently has a consensus target price of C$3.13, suggesting a potential upside of 167.09%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than CanniMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 CanniMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, OGI or CMED?

CanniMed Therapeutics has lower revenue, but higher earnings than Organigram. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.55 -C$57.23M C$0.60 1.95 CanniMed Therapeutics N/A N/A N/A N/A N/A

Which has higher valuation and earnings, OGI or TLRY?

Organigram has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.55 -C$57.23M C$0.60 1.95 Tilray Brands C$963.10M 0.54 -C$183.24M -C$1.41 N/A

Is OGI or TLRY more profitable?

Organigram has a net margin of 28.02% compared to Tilray Brands' net margin of -18.92%. Organigram's return on equity of 21.99% beat Tilray Brands' return on equity. Company Net Margins Return on Equity Return on Assets Organigram 28.02% 21.99% -5.56% Tilray Brands -18.92% -11.41% -1.41%

Do analysts prefer OGI or FRX?

Organigram currently has a consensus target price of C$3.13, indicating a potential upside of 167.09%. Given Organigram's higher probable upside, equities research analysts clearly believe Organigram is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has better valuation and earnings, OGI or ACB?

Aurora Cannabis has higher revenue and earnings than Organigram. Aurora Cannabis is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.55 -C$57.23M C$0.60 1.95 Aurora Cannabis C$321.28M 1.37 -C$44.16M -C$1.36 N/A

Which has higher earnings & valuation, OGI or WEED?

Organigram has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organigram C$309.18M 0.55 -C$57.23M C$0.60 1.95 Canopy Growth C$308.32M 1.08 -C$1.05B -C$0.79 N/A

Organigram (OGI) Competitors

C$1.17 -0.02 (-1.68%)

As of 10:21 AM Eastern

Compare

OGI vs. CMED, TLRY, FRX, ACB, and WEED

Should you buy Organigram stock or one of its competitors? Organigram's main competitors and comparable companies include CanniMed Therapeutics (CMED), Tilray Brands (TLRY), Fennec Pharmaceuticals (FRX), Aurora Cannabis (ACB), and Canopy Growth (WEED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Organigram compare to CanniMed Therapeutics?

Organigram (TSE:OGI) and CanniMed Therapeutics (TSE:CMED) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

CanniMed Therapeutics has lower revenue, but higher earnings than Organigram.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.55	-C$57.23M	C$0.60	1.95
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A

In the previous week, Organigram's average media sentiment score of 0.00 equaled CanniMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
Organigram	Neutral
CanniMed Therapeutics	Neutral

3.3% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Organigram has a net margin of 28.02% compared to CanniMed Therapeutics' net margin of 0.00%. Organigram's return on equity of 21.99% beat CanniMed Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
CanniMed Therapeutics	N/A	N/A	N/A

Organigram currently has a consensus target price of C$3.13, suggesting a potential upside of 167.09%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than CanniMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Organigram beats CanniMed Therapeutics on 8 of the 9 factors compared between the two stocks.

How does Organigram compare to Tilray Brands?

Organigram (TSE:OGI) and Tilray Brands (TSE:TLRY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Organigram has a beta of 1.440608, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.020364, suggesting that its stock price is 202% more volatile than the broader market.

In the previous week, Tilray Brands had 1 more articles in the media than Organigram. MarketBeat recorded 1 mentions for Tilray Brands and 0 mentions for Organigram. Organigram's average media sentiment score of 0.00 equaled Tilray Brands'average media sentiment score.

Company	Overall Sentiment
Organigram	Neutral
Tilray Brands	Neutral

Organigram currently has a consensus price target of C$3.13, suggesting a potential upside of 167.09%. Tilray Brands has a consensus price target of C$13.30, suggesting a potential upside of 278.92%. Given Tilray Brands' higher possible upside, analysts plainly believe Tilray Brands is more favorable than Organigram.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Organigram has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.55	-C$57.23M	C$0.60	1.95
Tilray Brands	C$963.10M	0.54	-C$183.24M	-C$1.41	N/A

Organigram has a net margin of 28.02% compared to Tilray Brands' net margin of -18.92%. Organigram's return on equity of 21.99% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Tilray Brands	-18.92%	-11.41%	-1.41%

3.3% of Organigram shares are owned by institutional investors. Comparatively, 4.1% of Tilray Brands shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Comparatively, 0.7% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Organigram beats Tilray Brands on 9 of the 15 factors compared between the two stocks.

How does Organigram compare to Fennec Pharmaceuticals?

Organigram (TSE:OGI) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Organigram currently has a consensus target price of C$3.13, indicating a potential upside of 167.09%. Given Organigram's higher probable upside, equities research analysts clearly believe Organigram is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Fennec Pharmaceuticals has lower revenue, but higher earnings than Organigram. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.55	-C$57.23M	C$0.60	1.95
Fennec Pharmaceuticals	C$59.22M	9.59	-C$800.44K	-C$0.12	N/A

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Organigram. MarketBeat recorded 1 mentions for Fennec Pharmaceuticals and 0 mentions for Organigram. Fennec Pharmaceuticals' average media sentiment score of 0.44 beat Organigram's score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Organigram	Neutral
Fennec Pharmaceuticals	Neutral

3.3% of Organigram shares are held by institutional investors. Comparatively, 16.8% of Fennec Pharmaceuticals shares are held by institutional investors. 31.3% of Organigram shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Organigram has a beta of 1.440608, meaning that its share price is 44% more volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.899825, meaning that its share price is 290% more volatile than the broader market.

Organigram has a net margin of 28.02% compared to Fennec Pharmaceuticals' net margin of -6.21%. Organigram's return on equity of 21.99% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

Summary

Fennec Pharmaceuticals beats Organigram on 9 of the 17 factors compared between the two stocks.

How does Organigram compare to Aurora Cannabis?

Organigram (TSE:OGI) and Aurora Cannabis (TSE:ACB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Organigram has a net margin of 28.02% compared to Aurora Cannabis' net margin of -28.05%. Organigram's return on equity of 21.99% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Aurora Cannabis	-28.05%	-15.31%	-1.87%

3.3% of Organigram shares are owned by institutional investors. Comparatively, 4.4% of Aurora Cannabis shares are owned by institutional investors. 31.3% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aurora Cannabis has higher revenue and earnings than Organigram. Aurora Cannabis is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.55	-C$57.23M	C$0.60	1.95
Aurora Cannabis	C$321.28M	1.37	-C$44.16M	-C$1.36	N/A

In the previous week, Aurora Cannabis had 7 more articles in the media than Organigram. MarketBeat recorded 7 mentions for Aurora Cannabis and 0 mentions for Organigram. Aurora Cannabis' average media sentiment score of 0.61 beat Organigram's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
Organigram	Neutral
Aurora Cannabis	Positive

Organigram currently has a consensus price target of C$3.13, indicating a potential upside of 167.09%. Aurora Cannabis has a consensus price target of C$6.60, indicating a potential downside of 7.17%. Given Organigram's stronger consensus rating and higher probable upside, equities research analysts clearly believe Organigram is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aurora Cannabis	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Organigram has a beta of 1.440608, indicating that its stock price is 44% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.25833, indicating that its stock price is 74% less volatile than the broader market.

Summary

Organigram beats Aurora Cannabis on 9 of the 16 factors compared between the two stocks.

How does Organigram compare to Canopy Growth?

Organigram (TSE:OGI) and Canopy Growth (TSE:WEED) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

In the previous week, Canopy Growth had 3 more articles in the media than Organigram. MarketBeat recorded 3 mentions for Canopy Growth and 0 mentions for Organigram. Canopy Growth's average media sentiment score of 0.85 beat Organigram's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Organigram	Neutral
Canopy Growth	Positive

Organigram has a net margin of 28.02% compared to Canopy Growth's net margin of -89.20%. Organigram's return on equity of 21.99% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram	28.02%	21.99%	-5.56%
Canopy Growth	-89.20%	-39.36%	-3.83%

Organigram has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$309.18M	0.55	-C$57.23M	C$0.60	1.95
Canopy Growth	C$308.32M	1.08	-C$1.05B	-C$0.79	N/A

3.3% of Organigram shares are owned by institutional investors. Comparatively, 4.2% of Canopy Growth shares are owned by institutional investors. 31.3% of Organigram shares are owned by insiders. Comparatively, 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Organigram presently has a consensus target price of C$3.13, indicating a potential upside of 167.09%. Canopy Growth has a consensus target price of C$1.88, indicating a potential upside of 137.34%. Given Organigram's higher possible upside, equities research analysts plainly believe Organigram is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Organigram has a beta of 1.440608, indicating that its share price is 44% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 2.06524, indicating that its share price is 107% more volatile than the broader market.

Summary

Organigram beats Canopy Growth on 8 of the 14 factors compared between the two stocks.

Get Organigram News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGI vs. The Competition

Export

Metric	Organigram	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$168.66M	C$13.74B	C$7.83B	C$12.99B
Dividend Yield	N/A	2.56%	2.46%	4.73%
P/E Ratio	1.95	29.54	34.53	30.41
Price / Sales	0.55	7.59	8.92	3.88
Price / Cash	3.85	15.79	22.23	34.92
Price / Book	0.33	4.94	4.39	3.52
Net Income	-C$57.23M	C$2.87B	C$3.51B	C$299.09M
7 Day Performance	-6.40%	0.05%	-1.39%	0.07%
1 Month Performance	-11.36%	-3.93%	-3.74%	-2.28%
1 Year Performance	-45.83%	-6.40%	1.07%	14.41%

Organigram Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGI Organigram	3.4212 of 5 stars	C$1.17 -1.7%	C$3.13 +167.1%	-47.1%	C$168.66M	C$309.18M	1.95	1,139
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
TLRY Tilray Brands	1.1579 of 5 stars	C$4.11 +10.5%	C$13.30 +223.6%	-79.5%	C$607.41M	C$963.10M	N/A	3,595
FRX Fennec Pharmaceuticals	0.0393 of 5 stars	C$14.99 flat	N/A	+46.2%	C$525.65M	C$59.22M	N/A	10	News Coverage
ACB Aurora Cannabis	0.465 of 5 stars	C$7.25 +0.6%	C$6.67 -8.0%	+12.1%	C$449.19M	C$314.07M	N/A	1,028

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:OGI) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organigram (OGI) Competitors

OGI vs. CMED, TLRY, FRX, ACB, and WEED

How does Organigram compare to CanniMed Therapeutics?

Summary

How does Organigram compare to Tilray Brands?

Summary

How does Organigram compare to Fennec Pharmaceuticals?

Summary

How does Organigram compare to Aurora Cannabis?

Summary

How does Organigram compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organigram (OGI) Competitors

OGI vs. CMED, TLRY, FRX, ACB, and WEED

How does Organigram compare to CanniMed Therapeutics?

Which has better valuation & earnings, OGI or CMED?

Does the media refer more to OGI or CMED?

Do insiders & institutionals hold more shares of OGI or CMED?

Is OGI or CMED more profitable?

Do analysts rate OGI or CMED?

Summary

How does Organigram compare to Tilray Brands?

Which has more volatility and risk, OGI or TLRY?

Does the media favor OGI or TLRY?

Do analysts prefer OGI or TLRY?

Which has higher valuation and earnings, OGI or TLRY?

Is OGI or TLRY more profitable?

Do insiders and institutionals hold more shares of OGI or TLRY?

Summary

How does Organigram compare to Fennec Pharmaceuticals?

Do analysts prefer OGI or FRX?

Which has stronger earnings & valuation, OGI or FRX?

Does the media refer more to OGI or FRX?

Do insiders and institutionals believe in OGI or FRX?

Which has more risk and volatility, OGI or FRX?

Is OGI or FRX more profitable?

Summary

How does Organigram compare to Aurora Cannabis?

Is OGI or ACB more profitable?

Do insiders & institutionals believe in OGI or ACB?

Which has better valuation and earnings, OGI or ACB?

Does the media favor OGI or ACB?

Do analysts recommend OGI or ACB?

Which has more risk and volatility, OGI or ACB?

Summary

How does Organigram compare to Canopy Growth?

Does the media refer more to OGI or WEED?

Is OGI or WEED more profitable?

Which has higher earnings & valuation, OGI or WEED?

Do institutionals and insiders believe in OGI or WEED?

Do analysts recommend OGI or WEED?

Which has more volatility and risk, OGI or WEED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools